Last Updated : June 9, 2023
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area Sort descending | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Firazyr | icatibant | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | |||
| Latuda | lurasidone | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | |||
| Orilissa | elagolix | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | |||
| Keytruda | Pembrolizumab | |||||
| Lynparza | Olaparib | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | |||
| Viibryd | vilazodone | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | |||
| Imbruvica | ibrutinib | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | ||||
| Revolade | eltrombopag | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | |||
| Symdeko | tezacaftor/ivacaftor | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | |||
| Tecentriq | Atezolizumab | Withdrawn |
Last Updated : June 9, 2023